-
Spatially Concentrated ABEs Correct PLP1 Mutations
2026-09-20
The reference study introduces spatially concentrated adenine base editors that improve pathogenic PLP1 correction in oligodendrocytes by locally enriching the TadA* deaminase near genomic targets. Its compact, AAV-compatible design combines stronger on-target editing with reduced transcriptome-wide RNA off-target activity, providing a mechanistic framework for difficult-to-edit myelinating cells.
-
o-Agatoxin IVA and Excitotoxicity in Cortical Neurons
2026-09-19
Lustig, Ahern, and Greenberg tested whether blocking P/Q-type calcium channels with α-agatoxin IVA protects cultured cortical neurons from excitotoxic injury. The toxin failed to reduce injury caused by veratridine, ouabain, or NMDA, showing that inhibition of depolarization-evoked glutamate release does not necessarily translate into neuroprotection.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-09-18
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different components of drug response. The work provides a practical framework for separating proliferation arrest from cell killing, improving interpretation of cancer drug screens and preclinical studies.
-
VER 155008: Mapping HSP70 Stress Biology
2026-09-17
VER 155008 is an adenosine-derived HSP 70 inhibitor that can be used to interrogate how chaperone activity shapes protein condensation, apoptosis, and cancer phenotypes. This article develops an assay strategy connecting Hsp70 ATPase inhibition with TDP-43 condensate biology while clearly separating established evidence from experimental hypotheses.
-
NSC-23766: Rac GTPase Inhibitor Workflows
2026-09-17
Build cleaner Rac1 loss-of-function experiments across breast cancer, endothelial barrier, and metabolic assays with NSC-23766 trihydrochloride. This workflow separates direct pathway inhibition from downstream effects and translates a new GPR81–FARP1–RAC1 glucose-uptake finding into testable assay designs.
-
Streptavidin-FITC for Mechanistic Assay Design
2026-09-16
Streptavidin-FITC can do more than reveal biotin: it can help separate molecular localization, cellular uptake, and functional delivery. This guide explains how to use fluorescein isothiocyanate conjugated streptavidin in mechanistically rigorous imaging, flow cytometry, and LNP-related workflows.
-
Entinostat (MS-275) Workflow for Cancer Research
2026-09-16
Build more informative Entinostat assays by separating growth arrest from cell killing and pairing viability with target-engagement measurements. This workflow connects HDAC1/3-focused pharmacology with cancer cell proliferation inhibition, retinoblastoma treatment research, and translational study design.
-
Dasatinib (BMS-354825) Research Workflows
2026-09-15
Build reproducible Src and Bcr-Abl signaling experiments with Dasatinib (BMS-354825), from phosphoprotein target engagement to migration and metastasis assays. This workflow also shows how to use the compound as a mechanistic comparator when studying EMT, cancer stem cell-like states, and the SNAI1–PIK3R2/p-EphA2 axis.
-
o-Agatoxin IVA and Excitotoxicity in Cortical Cultures
2026-09-15
Lustig, Ahern, and Greenberg tested whether blocking P- and Q-type voltage-gated calcium channels with ω-agatoxin IVA could protect cortical neurons from several excitotoxic insults. The study found no reduction in neuronal injury, showing that inhibition of presynaptic glutamate release does not necessarily translate into protection from downstream excitotoxic cell death.
-
Veratridine Workflows for Sodium Channel Assays
2026-09-14
Veratridine provides a controllable depolarization trigger for sodium channel dynamics research, excitotoxicity studies, and blocker screening. Its value also extends to chamber-specific cardiac models, where carefully validated right ventricular-like cardiomyocytes can reveal differences that mixed hPSC-cardiomyocyte populations obscure.
-
Carvedilol Phosphate: A New Lens on Hepatic IRI
2026-09-14
A translational framework for using Carvedilol Phosphate to interrogate adrenergic GPCR signaling, hepatocyte–macrophage crosstalk, and Arrb2-linked mechanisms in hepatic ischemia–reperfusion injury research.
-
Mifepristone (RU486) Workflows for Cancer Research
2026-09-13
Mifepristone (RU486) combines progesterone receptor blockade with a practical dose range for cancer, reproductive, and receptor-context experiments. This guide translates receptor heterogeneity into better controls, dose–response workflows, and troubleshooting decisions without overstating what the evidence proves.
-
DAPT in Hepatobiliary Organoid Research
2026-09-12
DAPT (GSI-IX) can turn hiPSC-derived hepatobiliary organoids into a mechanistic test system for γ-secretase and Notch signaling. This article connects staged organoid differentiation with causal pathway perturbation, functional readouts, formulation controls, and translational limitations.
-
U 46619: Designing Better TP-Receptor Assays
2026-09-12
U 46619, also known as 11,9 epoxymethano-prostaglandin H2, is a powerful tool for resolving the timing of TP-receptor signaling. This guide connects its platelet and vascular pharmacology with endpoint selection, dose interpretation, and translational assay design.
-
MK-0812: A Translational Lens on CCR2 in MASH
2026-09-11
A thought-leadership framework for using MK-0812 to test whether CCR2-dependent monocyte recruitment links intestinal TM6SF2 deficiency, gut–liver dysfunction, and hepatic inflammation in MASH models.